Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 1;10(21):9721–9740. doi: 10.7150/thno.44342

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Knocking down expression of AURKB would induce less additional apoptosis when BRAF/MEK/ERKs and PI3-K/AKT pathways were inhibited. (A, B) The apoptosis rate after knocking down expression of AURKB with non-treatment, LY294002 treatment, vemurafenib treatment and the combination of LY294002 and vemurafenib treatment in A375 cells. (C) The absolute change of apoptosis rate (shAURKB - shcontrol) among A375 cells with non-treatment, LY294002 treatment, vemurafenib treatment and the combination of LY294002 and vemurafenib treatment. (D, E) The apoptosis rate after knocking down expression of AURKB with non-treatment, LY294002 treatment, vemurafenib treatment and the combination of LY294002 and vemurafenib treatment in A375R cells. (F) The absolute change of apoptosis rate among A375R cells with non-treatment, LY294002 treatment, vemurafenib treatment and the combination of LY294002 and vemurafenib treatment. Statistical significance was determined by one-way ANOVA and the asterisks indicate a significant change compared with the control group (**, p < 0.01, ***, p < 0.001).